2,200 Shares in Natera, Inc. (NASDAQ:NTRA) Purchased by Maven Securities LTD

Maven Securities LTD purchased a new stake in Natera, Inc. (NASDAQ:NTRA) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 2,200 shares of the medical research company’s stock, valued at approximately $348,000.

Several other large investors have also recently added to or reduced their stakes in NTRA. Price T Rowe Associates Inc. MD increased its stake in shares of Natera by 134.9% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 6,742,428 shares of the medical research company’s stock valued at $1,067,327,000 after buying an additional 3,871,862 shares in the last quarter. JPMorgan Chase & Co. increased its position in Natera by 43.7% in the 4th quarter. JPMorgan Chase & Co. now owns 6,701,425 shares of the medical research company’s stock valued at $1,060,836,000 after acquiring an additional 2,036,396 shares in the last quarter. Norges Bank bought a new position in shares of Natera in the fourth quarter worth about $224,040,000. Raymond James Financial Inc. acquired a new position in shares of Natera during the fourth quarter worth approximately $146,419,000. Finally, Vanguard Group Inc. grew its stake in shares of Natera by 7.7% during the fourth quarter. Vanguard Group Inc. now owns 12,316,470 shares of the medical research company’s stock valued at $1,949,697,000 after purchasing an additional 879,463 shares during the last quarter. 99.90% of the stock is owned by institutional investors.

Natera Price Performance

NTRA stock opened at $152.28 on Wednesday. Natera, Inc. has a 1 year low of $92.14 and a 1 year high of $183.00. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.39 and a quick ratio of 4.23. The stock has a market cap of $20.59 billion, a price-to-earnings ratio of -86.52 and a beta of 1.79. The company has a 50 day simple moving average of $147.91 and a 200 day simple moving average of $156.15.

Natera (NASDAQ:NTRA) last announced its quarterly earnings results on Thursday, May 8th. The medical research company reported ($0.50) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.59) by $0.09. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The firm had revenue of $501.83 million during the quarter, compared to analysts’ expectations of $446.68 million. During the same period in the prior year, the company posted ($0.56) EPS. The company’s revenue was up 36.5% on a year-over-year basis. Research analysts anticipate that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Insider Transactions at Natera

In related news, insider Solomon Moshkevich sold 6,000 shares of the stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $143.29, for a total value of $859,740.00. Following the transaction, the insider now directly owns 143,768 shares in the company, valued at $20,600,516.72. This trade represents a 4.01% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Steven Leonard Chapman sold 87,272 shares of the stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $143.40, for a total value of $12,514,804.80. Following the completion of the sale, the chief executive officer now directly owns 203,354 shares of the company’s stock, valued at approximately $29,160,963.60. This trade represents a 30.03% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 152,436 shares of company stock worth $22,019,079 over the last ninety days. 7.60% of the stock is owned by insiders.

Wall Street Analyst Weigh In

NTRA has been the topic of several research reports. BTIG Research reaffirmed a “buy” rating on shares of Natera in a research note on Friday, February 28th. Piper Sandler raised their target price on shares of Natera from $200.00 to $205.00 and gave the company an “overweight” rating in a research note on Tuesday, March 4th. StockNews.com upgraded shares of Natera from a “sell” rating to a “hold” rating in a research report on Friday, May 9th. Morgan Stanley increased their price objective on shares of Natera from $176.00 to $185.00 and gave the company an “overweight” rating in a report on Wednesday, March 5th. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and issued a $180.00 price objective on shares of Natera in a research note on Wednesday, February 26th. One research analyst has rated the stock with a hold rating and sixteen have given a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $181.82.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.